Therefore, we defined the expression level of 700 amol/μg as an important indicator for distinguishing between intestinal and non-intestinal types of mixed-type gastric adenocarcinoma and as a reference threshold for the potential benefit of anti-HER2 targeted therapy in this type of patient. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.